{
    "clinical_study": {
        "@rank": "156316", 
        "arm_group": [
            {
                "arm_group_label": "Group 1"
            }, 
            {
                "arm_group_label": "Group 2"
            }
        ], 
        "brief_summary": {
            "textblock": "In COPD the patient's ability to use inhalers correctly and their preference for the inhaler\n      are both important factors in selecting an appropriate treatment for COPD. This  is a\n      cross-sectional study where satisfaction, preference and handling of two different devices\n      such as Respimat and Breezhaler will be evaluated by using the validated PASAPQ in COPD\n      patients"
        }, 
        "brief_title": "Preference Tiotropium Respimat Study in COPD", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Purpose:\n\n      Study Design:"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. All patients must sign an informed consent consistent with International Conference\n             on Harmonization - Good Clinical Practice (ICH-GCP) guidelines prior to participation\n             in the study and conducting any study procedures.\n\n          2. Adult male or female patients with chronic obstructive pulmonary disease (COPD) for\n             less than a year who follow usual clinical practice of the participant sites and who\n             are on treatment with Spiriva\u00ae Respimat\u00ae, Hirobriz\u00ae Breezhaler\u00ae / Onbrez\u00ae Breezhaler\u00ae\n             / Oslif\u00ae Breezhaler\u00ae for at least of 3 months but not more than maximum of 6 months\n             before the informed consent date.\n\n        Exclusion criteria:\n\n          1. Previously included in this study or currently participating in another\n             interventional study.\n\n          2. Visual, cognitive, or motor impairment that as judged by the investigator does not\n             allow the patient to independently read and complete the questionnaire.\n\n          3. Patients who are treated simultaneously with both respiratory medications (Spiriva\u00ae\n             Respimat\u00ae and Hirobriz\u00ae Breezhaler\u00ae / Onbrez\u00ae Breezhaler\u00ae / Oslif\u00ae Breezhaler\u00ae)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "COPD"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810692", 
            "org_study_id": "205.514"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1", 
                "description": "COPD patients using Respimat\u00ae", 
                "intervention_name": "Group1:Spiriva\u00ae Respimat\u00ae", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "COPD patients using Breezhaler\u00ae\u00ae", 
                "intervention_name": "Group2:Hirobriz\u00ae/Oslif\u00ae/Onbrez\u00ae Breezhaler\u00ae", 
                "intervention_type": "Device"
            }
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "A Coru\u00f1a", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 13"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 8"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 5"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 6"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burgos", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 12"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galdako.", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 14"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Laredo", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 11"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00e1laga", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 1"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00e9rida", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 3"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca.", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 15"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pozuelo de Alarc\u00f3n", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 9"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sabadell", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 7"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 2"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torrelodones", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 10"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villanueva de la Serena", 
                        "country": "Spain"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 4"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "2", 
        "official_title": "Cross-sectional Study to Assess the Handling , Patient Satisfaction, and Preference for Inhalation Devices in Patients With Chronic Obstructive Pulmonary Disease (COPD).", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Total score of the validated patient satisfaction and preference questionnaire (PASAPQ)", 
            "safety_issue": "No", 
            "time_frame": "At the time of the visit (day 1)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810692"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "performance score domain", 
                "safety_issue": "No", 
                "time_frame": "At the time of the visit (Day 1)"
            }, 
            {
                "measure": "Convenience score domain", 
                "safety_issue": "No", 
                "time_frame": "At the time of the visit (Day 1)"
            }, 
            {
                "measure": "Overall satisfaction question", 
                "safety_issue": "No", 
                "time_frame": "AT the time of the visit (Day 1)"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}